EUVIMEDEUVIMED entdecken
Fallbericht

Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA mutation: A case report

Emma Zattarin iD, Teresa Beninato iD, Giorgia Di Liberti, Daniele Lorenzini, Andrea Vingiani iD, Rita Leporati iD, Mario Occhipinti iD, Marta Brambilla iD

Tumori Journal · 2025

DOI: 10.1177/03008916251353357 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Tumori Journal, 2025. Verfasst von Emma Zattarin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Carcinoma, Neuroendocrine, Breast Neoplasms, Mutation. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The distinction between a metastatic recurrence and the onset of a second primary malignancy can be diagnostically challenging. Precision medicine can offer valuable support in this context. Case Presentation: A 34-year-old woman was diagnosed in 2012 with hormone-receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in the left breast, with homolateral axillary node involvement but no distant metastases. Following neoadjuvant chemotherapy, surgery (pathological stage was ypT1b ypN2a M0), adjuvant endocrine therapy and radiotherapy, she remained disease-free until 2021, when a positron emission tomography scan showed a mediastinal mass. Histology revealed a high-grade large cell neuroendocrine carcinoma (LCNEC) lacking breast cancer-specific markers (GATA3-, HR-, HER2-, mammoglobin-, GCDFP15-), with PD-L1 expression at 10% and a tumor mutational burden (TMB) of 9.54 mut/MB. Chemotherapy (cisplatin plus etoposide) led to rapid disease progression, whereas second-line pembrolizumab led to a remarkable and prolonged disease response. Treatment was discontinued in 2023 due to grade 3 immune-related colitis and, as of November 2024, the patient shows no clinical evidence of disease. Molecular analysis: Next-generation sequencing identified shared tumor PIK3CA pathogenic variants in both breast cancer and LCNEC tissues, suggesting a potential relationship as primary tumor and metastasis, rather than two distinct malignancies.

Conclusions

Molecular characterization of cancer enabled the identification of potential causal links between tumors with distinct histologies and locations, offering a deeper insight into an atypical clinical scenario.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesCarcinoma, NeuroendocrineBreast NeoplasmsMutationCarcinoma, Large CellHumansFemaleAdultBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant Therapy

Stichwörter der Autor:innen

Breast cancerlarge cell neuroendocrine carcinomamolecular tumor boardpembrolizumabsomatic mutations

Substanzen

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

ORCID-Profile: Emma Zattarin, Teresa Beninato, Andrea Vingiani, Rita Leporati, Mario Occhipinti, Marta Brambilla

Zitieren

APA

Zattarin, E., Beninato, T., Di Liberti, G., Lorenzini, D., Vingiani, A., Leporati, R., Occhipinti, M., & Brambilla, M. (2025). Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA mutation: A case report. Tumori Journal. https://doi.org/10.1177/03008916251353357

Vancouver

Zattarin E, Beninato T, Di Liberti G, Lorenzini D, Vingiani A, Leporati R, et al. Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA mutation: A case report. Tumori Journal. 2025. doi:10.1177/03008916251353357

BibTeX
@article{Zattarin2025,
  author = {Zattarin, Emma and Beninato, Teresa and Di Liberti, Giorgia and Lorenzini, Daniele and Vingiani, Andrea and Leporati, Rita and Occhipinti, Mario and Brambilla, Marta},
  title = {Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA mutation: A case report},
  journal = {Tumori Journal},
  year = {2025},
  doi = {10.1177/03008916251353357}
}
Kostenlos starten →